Journal article
Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation Insights From ARTESiA
Abstract
BACKGROUND: ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) demonstrated that apixaban, compared with aspirin, significantly reduced stroke and systemic embolism (SE) but increased major bleeding in patients with subclinical atrial fibrillation.
OBJECTIVES: To help inform decision making, the authors evaluated the efficacy and safety of apixaban according to baseline CHA2…
Authors
Lopes RD; Granger CB; Wojdyla DM; McIntyre WF; Alings M; Mani T; Ramasundarahettige C; Rivard L; Atar D; Birnie DH
Journal
Journal of the American College of Cardiology, Vol. 84, No. 4, pp. 354–364
Publisher
Elsevier
Publication Date
July 2024
DOI
10.1016/j.jacc.2024.05.002
ISSN
0735-1097